NCT04246190

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.

Detailed description

Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults

Conditions

• Type2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	CKD-501 and D759	Reference drug, CKD-501 1T and D759 1T, QD, PO
DRUG	CKD-396	Reference drug, CKD-396 1T, QD, PO

Timeline

• Start date: 2020-02-24
• Primary completion: 2020-04-10
• Completion: 2020-07-16
• First posted: 2020-01-29
• Last updated: 2020-02-05

Locations

1 site across 1 country: South Korea